Glucosamine and Alzheimer's Disease: What the 2026 Study Found

Table of Contents

1. Overview: Why Alzheimer's Entered the Glucosamine Story
2. The Studies at a Glance
3. What the Mice and Brain Tissue Showed
4. What the Health Records Showed
5. The Re-Check: The Same Signal for Multivitamins
6. UK Biobank: Lower or No Risk in People Without Dementia
7. Why the Studies Disagree
8. One Pathway, Two Kinds of Sugar Tag
9. What This Means for You
10. What Is Not Known
11. Key Research Papers
12. Connections
13. Featured Videos

Overview: Why Alzheimer's Entered the Glucosamine Story

Glucosamine feeds the hexosamine pathway, the same route the body uses to make its own glucosamine from glucose and glutamine (see How the Body Makes Glucosamine). The pathway's end product, UDP-GlcNAc, is the raw material for the sugar chains attached to proteins. One of those families of chains, the N-linked glycans, sits on many proteins of the brain's surface membranes.

The 2026 study asked a simple question: is there too much of this glycosylation in Alzheimer's disease, and if so, is it a cause or a by-product? Its answer was that it is a driver, and that glucosamine, which pushes more sugar into this pathway, made things worse (Hawkinson 2026).

Back to Table of Contents

The Studies at a Glance

HR is the hazard ratio: below 1 means the event was less common among glucosamine users, above 1 more common. None of the human studies is a randomized trial.

Back to Table of Contents

What the Mice and Brain Tissue Showed

The research team, led from the University of Florida with collaborators at several U.S. centers, used imaging methods that map metabolites, fats and sugar chains directly on slices of brain tissue. They looked at transgenic Alzheimer's mouse models and at post-mortem human Alzheimer's brain (Hawkinson 2026).

• A shared pattern. Both the mouse and the human Alzheimer's brains showed "hyperglycosylation", more sugar chains on proteins than normal.
• Made, not just left over. By feeding labelled nutrients and tracking them over time, the team showed the excess came from increased glycan biosynthesis, the brain building more chains, rather than failing to clear old ones.
• Turning it down helped. Genetically reducing the enzymes that build these chains "improves cognitive outcomes in AD mice".
• Glucosamine made it worse. "Oral glucosamine supplementation impairs them." In the earlier preprint version, the authors described glucosamine as having "drove hyper-glycosylation and exacerbated cognitive and behavioral deficits" (Hawkinson 2025 preprint).

These are mouse experiments. Mouse models of Alzheimer's carry human disease genes and do not capture everything about the human illness, and the doses and timing in mice are not the same as a person taking a supplement.

Back to Table of Contents

What the Health Records Showed

To see whether the mouse finding mattered in people, the team ran "a retrospective analysis of electronic health records from patients with AD with varying disease severity" and found that "glucosamine supplementation is associated with accelerated AD progression and worsened survival" (Hawkinson 2026). The preprint version describes the comparison as a large population of patients with mild cognitive impairment, Alzheimer's and related dementias, stratified by glucosamine use, with more progression from mild cognitive impairment to Alzheimer's and higher mortality among users (Hawkinson 2025 preprint).

Two points matter for reading this:

• These were people who already had cognitive decline. The question was how fast it progressed, not who developed it in the first place.
• It is an association. Health-record studies cannot show that glucosamine caused the faster decline. People who have glucosamine written in their records may differ in age, joint disease, mobility, other medicines, or simply in how thoroughly their supplements were recorded.

Back to Table of Contents

The Re-Check: The Same Signal for Multivitamins

Within weeks, a separate research group tested the health-record finding in a different source, the U.S. National Alzheimer's Coordinating Center cohort. They added a control the original analysis did not report: they compared glucosamine with other supplements recorded in the same medication fields (Nakashima 2026).

• For progression to Alzheimer's dementia, the estimate for glucosamine pointed "in the same risk direction as the original finding".
• But "similar estimates were observed for multivitamin/broad vitamin and calcium/vitamin D records".
• Among people who already had dementia, glucosamine records "were not associated with higher adjusted mortality", although gaps in death data reduce certainty.

Their conclusion: the findings "do not address the experimental mechanism, but show that a glucosamine record alone does not establish a glucosamine-specific clinical effect." In other words, the people taking any of these supplements progressed a little faster, which points to something about supplement users or record-keeping rather than to glucosamine itself. This re-check is a preprint and has not yet been peer reviewed.

Back to Table of Contents

UK Biobank: Lower or No Risk in People Without Dementia

Before 2026, four analyses of the UK Biobank, a study of about half a million British adults who reported their supplement use in 2006–2010, had looked at whether glucosamine users went on to develop dementia:

• Xu 2022: 18.8% of 495,942 participants used glucosamine. Over a median 11 years, users had a lower risk of dementia (HR 0.87). Part of the link ran through a lower rate of type 2 diabetes.
• Zheng 2023: users had lower risk of all-cause dementia (HR 0.84), Alzheimer's (HR 0.83) and vascular dementia (HR 0.74). A genetic analysis (Mendelian randomization) also suggested a protective relationship.
• Zhou 2023: among 214,945 adults over 60, followed for 12 years, glucosamine went with less vascular dementia (HR 0.82) but was "not significantly associated with incident Alzheimer's disease" (HR 1.02).
• Ai 2024: among about 290,000 adults, "Glucosamine intake was not associated with incident dementia" (HR 1.06) or Parkinson's disease.

A further genetic study linked a genetic tendency to take glucosamine with better cognitive test scores (Kang 2024). Genetic "tendency to take a supplement" studies are hard to interpret, because the genes involved shape behaviour and health in many ways besides the supplement.

These studies share a weakness: people who choose to take a joint supplement in middle age tend to be more health-conscious, better off and more active than those who do not, and no amount of statistical adjustment fully removes that. The same "healthy user" pattern is why the same database also linked glucosamine to less diabetes and heart disease (see Blood Sugar and Diabetes).

Back to Table of Contents

Why the Studies Disagree

Both sets of findings can be true at once. A substance could make no difference, or appear helpful, in healthy people, and still be harmful once the brain is already in the disease state where glycan building is turned up. That is a hypothesis, not a proven fact, but it is the reason this page treats people with memory problems differently.

Back to Table of Contents

One Pathway, Two Kinds of Sugar Tag

The confusion has a biological root. UDP-GlcNAc, the end product of the glucosamine pathway, is used in two very different ways:

• N-linked glycans: long, branched sugar chains built on proteins as they are made. This is the "hyperglycosylation" the 2026 study found in excess in Alzheimer's brain, and which glucosamine increased (Hawkinson 2026).
• O-GlcNAc: a single sugar clipped on and off proteins inside the cell, acting as a nutrient sensor (Hart 2007). Reviews describe it as protective in Alzheimer's, where it "blocks toxic changes in key proteins like tau and amyloid-beta" (Shao 2026). In a mouse model of brain inflammation, glucosamine raised O-GlcNAc, calmed the brain's immune cells and reduced memory loss (Kim 2026).

So laboratory research has pointed in opposite directions depending on which branch is measured. Earlier enthusiasm for glucosamine as a brain protector came from the O-GlcNAc side; the 2026 warning comes from the N-glycan side. Which effect wins in a human brain, at supplement doses, is not known.

Back to Table of Contents

What This Means for You

• The research raises a concern for people with memory problems, mild cognitive impairment or Alzheimer's disease. The concern is a possible risk, not a proven harm. The human evidence is a single health-record association that a re-check could not tie to glucosamine specifically, but the mouse experiments point the same way and there is no proven benefit to set against it.
• For everyone else, this does not change much. The earlier picture already stood: the body makes its own glucosamine, the joint trials found little or no benefit (what the trials found), and the research raises a concern for people with high blood sugar (blood sugar).
• The UK Biobank studies do not show that glucosamine protects the brain. They are associations in healthy volunteers with a known healthy-user bias, and no trial has tested glucosamine to prevent dementia.
• For a person with cognitive decline who already takes it, this is a question worth raising with the clinician who manages their care, separately from any other medicines.

For what is known about the disease itself, see Alzheimer's Disease.

Back to Table of Contents

What Is Not Known

• No randomized trial has tested glucosamine's effect on memory or Alzheimer's progression in people.
• Dose. Whether the amount of glucosamine that reaches the human brain from a 1,500 mg supplement is enough to change brain glycosylation is unknown; blood levels after such a dose are low (Biggee 2006).
• The peer-reviewed re-check. The comparator analysis that found the same signal for multivitamins is still a preprint.
• Diet. Whether high blood sugar, which also pushes more glucose into the hexosamine pathway, contributes to brain hyperglycosylation in people is an open question the 2026 study raises but does not answer.

Back to Table of Contents

Key Research Papers

1. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8(6):1410-1425. — doi:10.1038/s42255-026-01538-4 (PubMed PMID: 42265388)
2. Hawkinson TR, Liu Z, Ribas RA, et al. Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer's Disease. bioRxiv [preprint]. 2025:2025.04.30.651461. — doi:10.1101/2025.04.30.651461 (PubMed PMID: 40654813)
3. Nakashima S, Sato K, Niimi Y, et al. Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer's disease. medRxiv [preprint]. 2026:2026.07.23.26358748. — doi:10.64898/2026.07.23.26358748 (PubMed PMID: 42619916)
4. Xu C, Hou Y, Fang X, et al. The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study. Alzheimer's Research & Therapy. 2022;14(1):184. — doi:10.1186/s13195-022-01137-x (PubMed PMID: 36514123)
5. Zheng J, Ni C, Zhang Y, et al. Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study. BMC Medicine. 2023;21(1):114. — doi:10.1186/s12916-023-02816-8 (PubMed PMID: 36978077)
6. Zhou C, Zhang Y, Yang S, et al. Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population. Alzheimer's Research & Therapy. 2023;15(1):152. — doi:10.1186/s13195-023-01295-6 (PubMed PMID: 37689747)
7. Ai B, Chen L, Cai M, et al. No Associations Between Glucosamine Supplementation and Dementia or Parkinson's Disease: Findings From a Large Prospective Cohort Study. Journals of Gerontology Series A. 2024;79(2):glad123. — doi:10.1093/gerona/glad123 (PubMed PMID: 37158699)
8. Kang Y, Tang Y, Kong W, et al. Causality of genetically determined glucosamine supplementation on cognition and sarcopenia: a Mendelian randomization study. Frontiers in Endocrinology. 2024;15:1404308. — doi:10.3389/fendo.2024.1404308 (PubMed PMID: 39764251)
9. Kim DY, Kim SM, Lee C, et al. O-GlcNAcylation reprograms microglial inflammatory states and attenuates Alzheimer's disease pathology. Cell Death & Disease. 2026;17(1):638. — doi:10.1038/s41419-026-08862-3 (PubMed PMID: 42161925)
10. Shao N, Zhang X, Ge Y, et al. O-GlcNAcylation: A molecular switch linking brain health to neurodegeneration. Neural Regeneration Research. 2026;21(10):4715-4728. — doi:10.4103/NRR.NRR-D-25-00101 (PubMed PMID: 40903936)
11. Abul MS, Parvizi J, Skowronek P, et al. Osteoarthritis management through medical reversal: Glucosamine, Alzheimer's disease risk, and long-term outcomes after arthroscopic partial meniscectomy. Knee Surgery, Sports Traumatology, Arthroscopy. 2026. — doi:10.1002/ksa.70578 (PubMed PMID: 42573117)
12. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017-1022. — doi:10.1038/nature05815 (PubMed PMID: 17460662)
13. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Annals of the Rheumatic Diseases. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)

PubMed Topic Searches

1. PubMed: Glucosamine and Alzheimer's disease
2. PubMed: Glucosamine and dementia cohort studies
3. PubMed: N-glycosylation in the Alzheimer's brain
4. PubMed: O-GlcNAc, tau and Alzheimer's

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

• All Amino Acids
• Glucosamine
• How the Body Makes Glucosamine
• Glucosamine, Blood Sugar and Diabetes
• Glucosamine Safety
• Glucosamine for Joint Pain
• Glutamine Instead of Glucosamine?
• History of Glucosamine
• Alzheimer's Disease
• History of Alzheimer's Disease
• Vitamin B1, Cognition and Alzheimer's
• Insulin Resistance
• Type 2 Diabetes
• Osteoarthritis

Back to Table of Contents

Featured Videos